AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00662558
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg capsules BID for 6 weeks
Trial: NCT01551004
Drug: CRS3123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
Trial: NCT01542034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection
Trial: NCT01075399
Drug: [F 18]HX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with \[F 18\]HX4
Trial: NCT00115037
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparer for 16 weeks in phase 2.
Trial: NCT02449902
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 10 µg capsule inserted vaginally for 14 days.
Trial: NCT02449902
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule inserted vaginally for 14 days.
Trial: NCT03654105
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment will consist of Acetylsalicylic acid at 100mg once a day
Trial: NCT02612610
Drug: Placebo (for gefapixant)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04115410
Drug: Chemotherapy Drugs, Cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
Trial: NCT00783224
Drug: Placebo for MF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
Trial: NCT00783224
Drug: Placebo for FP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
Trial: NCT01060878
Drug: PYM50028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP
Trial: NCT01060878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo comprising identical vehicle to active doses
Trial: NCT04202263
Drug: Minocycline Topical
RxNorm normalized name: minocycline topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
Trial: NCT04202263
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placement of minocycline cream 0%
Trial: NCT02930746
Drug: BAY987516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-092)
Trial: NCT01904318
Drug: IDP-73152 mesylate 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-73152 mesylate 80 mg single dose administration
Trial: NCT01904318
Drug: IDP-73152 mesylate 160 mg
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-73152 mesylate 160 mg single dose administration
Trial: NCT01904318
Drug: IDP-73152 mesylate 320 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-73152 mesylate 320 mg single dose administration
Trial: NCT01904318
Drug: IDP-73152 mesylate 640 mg
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-73152 mesylate 640 mg single dose administration
Trial: NCT01904318
Drug: IDP-73152 mesylate 1280 mg
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-73152 mesylate 1280 mg single dose administration
Trial: NCT01904318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose administration
Trial: NCT01707251
Drug: Intravenous Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
Trial: NCT00195988
Drug: tacrolimus, steroids, mycophenolate mofetil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02791308
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03458923
Drug: Diclofenac Sodium 0.1 ml containing 500µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
Trial: NCT01080729
Drug: Recombinant-follicle stimulating hormone (r-FSH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml \[22 micrograms/0.5 ml\]; 450 IU/0.75 ml \[33 micrograms/0.75 ml\]; or 900 IU/1.5 ml \[66 micrograms/1.5 ml\].~The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG).
Trial: NCT03605940
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/day
Trial: NCT00179205
Drug: Nepro nutritional supplement
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
Trial: NCT00179205
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
Trial: NCT00546455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules/day
Trial: NCT00203060
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, once daily, 58 weeks
Trial: NCT02719834
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
Trial: NCT01986361
Drug: flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
Trial: NCT01986361
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
Trial: NCT00202774
Drug: (capecitabine, oxaliplatin, 5-fluorouracil)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02411175
Drug: 20% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01293201
Drug: STAHIST
RxNorm normalized name: Stahist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAHIST dosed one tablet, BID
Trial: NCT01293201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical in appearance to IMP, dosed one tablet BID
Trial: NCT00861315
Drug: Nebulized amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
Trial: NCT00861315
Drug: Intravenous amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/Kg amikacin are administred intravenousely once a day during three days.
Trial: NCT00861315
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline is administered intravenousely once a day during three days
Trial: NCT00966745
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01962376
Drug: Oxaliplatin;Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
Trial: NCT03837015
Drug: Estring Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
Trial: NCT03535532
Drug: standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
Trial: NCT01844973
Drug: M518101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proper quantity twice a day
Trial: NCT01844973
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proper quantity twice a day
Trial: NCT00096278
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00096278
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04631874
Drug: CDFF0318, Champix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
Trial: NCT00674765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day
Trial: NCT00604396
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01901861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is given before meal ingestion
Trial: NCT04421456
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
Trial: NCT04421456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
Trial: NCT02054442
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01472965
Drug: ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70% ethanol catheter lock therapy
Trial: NCT00628095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no active ingredient
Trial: NCT01897610
Drug: Immuncell-LC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour
Trial: NCT02555124
Drug: JNJ-42847922, 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
Trial: NCT02555124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
Trial: NCT03334318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets administered in the PERL Clinical Trial
Trial: NCT01274000
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02746783
Drug: Double dose of MUTAGRIP® influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
Trial: NCT02818621
Drug: Group Dex (dexmedetomidine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
Trial: NCT02348359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03422159
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Trial: NCT03422159
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
Trial: NCT03422159
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Trial: NCT02669914
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02499497
Drug: LY2452473
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
Trial: NCT02499497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive pills containing no active drug.
Trial: NCT01329588
Drug: Monthly antibiotic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
Trial: NCT01329588
Drug: Monthly placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
Trial: NCT00047229
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03515629
Drug: REGN2810/ipi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN2810 plus ipilimumab
Trial: NCT03515629
Drug: REGN2810/chemo/ipi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN2810 plus chemotherapy plus Ipilimumab
Trial: NCT03329248
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03329248
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03329248
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Trial: NCT03329248
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Trial: NCT00851773
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg once weekly, s.c. injection
Trial: NCT00851773
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg once weekly, s.c. injection
Trial: NCT00851773
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg once weekly, s.c. injection
Trial: NCT00851773
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
Trial: NCT00851773
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
Trial: NCT02538692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is the same as Tong-Xie-Yao-Fang in appearance.
Trial: NCT01053520
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
Trial: NCT01053520
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
Trial: NCT01053520
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
Trial: NCT00990067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules identical to MDMA or duloxetine
Trial: NCT00904839
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 100 and 150 mg capsules
Trial: NCT00904839
Drug: mFolfox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard i.v chemotherapy
Trial: NCT00904839
Drug: mFolfox 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV standard chemotherapy
Trial: NCT03197194
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one tablet of aspirin 300 mg
Trial: NCT03197194
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
Trial: NCT03197194
Drug: placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
Trial: NCT01364922
Drug: hydrocodone/acetaminophen extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01364922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04712032
Drug: ICG-guided bowel perfusion assessment
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
Trial: NCT03967197
Drug: Saline spray
RxNorm normalized name: Saline Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline spray
Trial: NCT01651273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 0 mg, Once daily, 28 days
Trial: NCT02080182
Drug: placebo acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01985256
Drug: Toca FC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02203513
Drug: LY2606368
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 105 mg/m\^2 intravenous (IV) once every 14 days of a 28 day cycle
Trial: NCT01441596
Drug: Investigator's choice of treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
Trial: NCT00070213
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00070213
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00070213
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00070213
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01323790
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg oral tablet once daily
Trial: NCT02854605
Drug: Placebo to match GS-9674
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT01323790
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral tablet once daily
Trial: NCT01323790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to NKTR-118